# Guangzhou Targene Biotech Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/guangzhou-targene-biotech-co

- Industry: Biotechnology
- Headquarters: Guangzhou, China
- Website: www.gztargene.com
- Total disclosed funding: $14M
- Latest round: Series A (Mar 27, 2020)
- Investors on record: 2

## About

Based in Guangzhou, China, and established in 2009, Guangzhou Targene Biotech Co., Ltd. is a biotechnology company that focuses on manufacturing, sales, and clinical application of in-vitro diagnostic reagents. The company has three subsidiaries, including Anhui Dajian Medical Technology Co., Ltd., Wuhu Dajian Medical Testing Laboratory, and Guangzhou United Easy Inspection Medical Laboratory Co. Ltd. The Wuhu Dajian Medical Testing Laboratory provides molecular testing services, including pathogen nucleic acid testing and early tumor testing. The Guangzhou United Easy Inspection Medical Laboratory Co. Ltd. has a pathology laboratory, gene sequencing lab, and PCR lab, and is equipped with molecular diagnostics platforms. 

The company provides molecular testing services, including early tumor diagnoses based on methylation testing technology. The in-vitro diagnostic reagents can be used for diagnostic colorectal cancer, bladder cancer, liver cancer, cervical carcinoma, and thyroid cancer.


The company will apply for product registration certifications, to expand its market shares, to promote the process of products under development, and to introduce talents.

## Funding rounds

- Series A, Mar 27, 2020, $14M — Shandong High-tech Investment Corporation, BGI Co-WIN Investment Management

## Investors

- Shandong High-tech Investment Corporation (https://capitalatlas.ai/funds/shandong-high-tech-investment-corporation) — Series A
- BGI Co-WIN Investment Management (https://capitalatlas.ai/funds/bgi-co-win-investment-management) — Series A